Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Oatly Group AB - ADR — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Oatly Group AB - ADR trades at $9.38 (market cap $301.32M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 14.9× Oatly Group AB - ADR's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| ACAD | OTLY | |
|---|---|---|
Market Cap | $4.49B | $301.32M |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $18.54 |
52-Week Low | $20.06 | $8.03 |
Enterprise Value | $3.69B | $798.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
OTLY trades at $9.65, down 3.02% today, with a bullish technical signal from moving averages and ADX indicators. Revenue grew to $862.46M in 2025, but the company reported a net loss of $152.77M, with negative cash flow and high debt levels. Recent news includes a partnership with Nespresso and upcoming Q2 2026 earnings on July 22, 2026.
The outlook remains challenging due to persistent losses and cash burn, though revenue growth and a strong brand offer potential. Key risks include high leverage and competitive pressures. Analysts are divided, with 44% buy ratings but 50% hold, reflecting cautious optimism amid financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
